Quick Answer
Amneal Pharmaceuticals, Inc. reported Net Income Loss of $72.06 million for the year ending 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +161.6% in Net Income Loss from 2024 to 2025.
- This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $0.00 | Q3 2017: $0.00 | Q4 2017: $0.00 | Q1 2018: $0.00 | Q2 2018: -$17.86 million | Q3 2018: $6.89 million | Q1 2019: -$47.88 million | Q2 2019: -$16.90 million | Q3 2019: -$265.01 million | Q1 2020: $120.43 million | Q2 2020: -$24.16 million | Q3 2020: -$21.64 million | Q1 2021: $12.75 million | Q2 2021: $29.99 million | Q3 2021: -$7.78 million | Q1 2022: -$8.82 million | Q2 2022: -$242.13 million | Q3 2022: -$7.61 million | Q1 2023: -$6.94 million | Q2 2023: $11.92 million | Q3 2023: $9.68 million | Q1 2024: -$91.64 million | Q2 2024: $5.99 million | Q3 2024: -$156.0 thousand | Q1 2025: $12.20 million | Q2 2025: $22.42 million | Q3 2025: $2.37 million.
- Historical annual values: Fiscal year 2025: $72.06 million | Fiscal year 2024: -$116.89 million | Fiscal year 2023: -$83.99 million | Fiscal year 2022: -$270.58 million | Fiscal year 2021: $13.16 million | Fiscal year 2020: $67.79 million | Fiscal year 2019: -$603.57 million | Fiscal year 2018: -$19.74 million | Fiscal year 2017: $0.00 | Fiscal year 2016: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: